scholarly journals Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers

2018 ◽  
Vol 8 ◽  
Author(s):  
Rama Soundararajan ◽  
Ana M. Aparicio ◽  
Christopher J. Logothetis ◽  
Sendurai A. Mani ◽  
Sankar N. Maity
Keyword(s):  
Tumor Suppressors ◽  
Epithelial Plasticity ◽  
Prostate Cancers ◽  
Antiandrogen Therapy ◽  
Aggressive Variant

scholarly journals EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers

2018 ◽  
Vol 1870 (2) ◽  
pp. 229-238 ◽  
Author(s):  
Rama Soundararajan ◽  
Anurag N. Paranjape ◽  
Sankar Maity ◽  
Ana Aparicio ◽  
Sendurai A. Mani
Keyword(s):  
Tumor Plasticity ◽  
Prostate Cancers ◽  
Aggressive Variant

scholarly journals Epithelial–Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics

Genes ◽  
2021 ◽  
Vol 12 (12) ◽  
pp. 1900
Author(s):  
Luiz Paulo Chaves ◽  
Camila Morais Melo ◽  
Fabiano Pinto Saggioro ◽  
Rodolfo Borges dos Reis ◽  
Jeremy Andrew Squire
Keyword(s):  
Prostate Cancer ◽  
Transcription Factors ◽  
Epithelial Mesenchymal Transition ◽  
Driver Genes ◽  
Mesenchymal Transition ◽  
Prostate Cancer Stem Cells ◽  
Slug Expression ◽  
Prostate Cancers ◽  
Castrate Resistant ◽  
Antiandrogen Therapy

Prostate cancers may reactivate a latent embryonic program called the epithelial–mesenchymal transition (EMT) during the development of metastatic disease. Through EMT, tumors can develop a mesenchymal phenotype similar to cancer stem cell traits that contributes to metastasis and variation in therapeutic responses. Some of the recurrent somatic mutations of prostate cancer affect EMT driver genes and effector transcription factors that induce the chromatin- and androgen-dependent epigenetic alterations that characterize castrate-resistant prostate cancer (CRPC). EMT regulators in prostate cancer comprise transcription factors (SNAI1/2, ZEB1, TWIST1, and ETS), tumor suppressor genes (RB1, PTEN, and TP53), and post-transcriptional regulators (miRNAs) that under the selective pressures of antiandrogen therapy can develop an androgen-independent metastatic phenotype. In prostate cancer mouse models of EMT, Slug expression, as well as WNT/β-Catenin and notch signaling pathways, have been shown to increase stemness potential. Recent single-cell transcriptomic studies also suggest that the stemness phenotype of advanced prostate cancer may be related to EMT. Other evidence correlates EMT and stemness with immune evasion, for example, activation of the polycomb repressor complex I, promoting EMT and stemness and cytokine secretion through RB1, TP53, and PRC1. These findings are helping clinical trials in CRPC that seek to understand how drugs and biomarkers related to the acquisition of EMT can improve drug response.

scholarly journals Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers

Diagnostics ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1109
Author(s):  
Francesca Giunchi ◽  
Francesco Massari ◽  
Annalisa Altimari ◽  
Elisa Gruppioni ◽  
Elisabetta Nobili ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Objective Response ◽  
Lung Nodule ◽  
Thoracic Wall ◽  
Lung Cancers ◽  
Molecular Alterations ◽  
First Case ◽  
Prostate Cancers ◽  
Cancer Of The Prostate ◽  
Antiandrogen Therapy

The TMPRSS2:ERG fusion is considered prostate specific and has been rarely described in other tumors. We describe the case of a patient who developed lung and prostate cancers, both harboring the TMPRSS2:ERG fusion. The patient developed a cancer of the prostate with lymph node metastases and after two years a nodule of the thoracic wall. The histology and immunohistochemical profile of the two tumors were typical of prostate and lung cancers. The presence of the TMPRSS2:ERG fusion was demonstrated by next-generation sequencing on both malignancies, leading to the assumption that the lung nodule was a metastasis from the prostate cancer. The patient failed to respond to antiandrogen therapy, while chemotherapy for lung cancer led to a significant objective response. To our knowledge, this is the first case of a lung cancer harboring the TMPRSS2:ERG fusion, widening the spectrum of lung cancer-associated molecular alterations.

scholarly journals Abstract 4674: Targeting cancer stem-cells in aggressive variant prostate cancers

2019 ◽  
Author(s):  
Rama Soundararajan ◽  
Paul Allegakoen ◽  
Petra den Hollander ◽  
Anurag Paranjape ◽  
Robiya Joseph ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Prostate Cancers ◽  
Aggressive Variant

scholarly journals Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

2015 ◽  
Vol 22 (6) ◽  
pp. 1520-1530 ◽  
Author(s):  
Ana M. Aparicio ◽  
Li Shen ◽  
Elsa Li Ning Tapia ◽  
Jing-Fang Lu ◽  
Hsiang-Chun Chen ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Combined Tumor ◽  
Prostate Cancers ◽  
Aggressive Variant

Abstract 5443: Modulating plasticity in aggressive variant prostate cancers

2020 ◽  
Author(s):  
Rama Soundararajan ◽  
Petra den Hollander ◽  
Peter Shepherd ◽  
Nora Navone ◽  
Daniele Lorenzini ◽  
...  
Keyword(s):  
Prostate Cancers ◽  
Aggressive Variant

Decreased protein expression of candidate tumor suppressors TET3 and EPB41L3 in prostate cancers

2020 ◽  
Vol 216 (2) ◽  
pp. 152815
Author(s):  
Ha Yoon Mo ◽  
Hyun Ji Son ◽  
Eun Ji Choi ◽  
Nam Jin Yoo
Keyword(s):  
Protein Expression ◽  
Tumor Suppressors ◽  
Prostate Cancers

scholarly journals Abstract 4674: Targeting cancer stem-cells in aggressive variant prostate cancers

2019 ◽  
Author(s):  
Rama Soundararajan ◽  
Paul Allegakoen ◽  
Petra den Hollander ◽  
Anurag Paranjape ◽  
Robiya Joseph ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Prostate Cancers ◽  
Aggressive Variant

471: Do Mul Tifocal Prostate Cancers have Worst Pathological Features than Unifocal Cancers?

2007 ◽  
Vol 177 (4S) ◽  
pp. 158-158
Author(s):  
Nicolas B. Delongchamps ◽  
Vishal Chandan ◽  
Richard Jones ◽  
Gregory Threatte ◽  
Mary Jumbelic ◽  
...  
Keyword(s):  
Pathological Features ◽  
Prostate Cancers

Characterizing finger palpation in the detection of prostate cancers and abnormalities

2008 ◽  
Author(s):  
Ninghuan Wang ◽  
Gregory J. Gerling ◽  
Reba Moyer Childress ◽  
Marcus L. Martin
Keyword(s):  
Prostate Cancers
Sign in / Sign up

Export Citation Format

Share Document